Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, Lattin J, Markovska M, Mozarsky B, Arias-Umana J, Hapke R, Jung IY, Wang A, Xu P, Klysz D, Zuern G, Bashti M, Quinn PJ, Miao Z, Sandor K, Zhang W, Chen GM, Ryu F, Logun M, Hall J, Tan K, Grupp SA, McClory SE, Lareau CA, Fraietta JA, Sotillo E, Satpathy AT, Mackall CL, Weber EW. Doan AE, et al. Among authors: grupp sa. Nature. 2024 May;629(8011):E11. doi: 10.1038/s41586-024-07450-9. Nature. 2024. PMID: 38654101 Free PMC article. No abstract available.
FOXO1 is a master regulator of CAR T memory programming.
Doan A, Mueller KP, Chen A, Rouin GT, Daniel B, Lattin J, Chen Y, Mozarsky B, Markovska M, Arias-Umana J, Hapke R, Jung I, Xu P, Klysz D, Bashti M, Quinn PJ, Sandor K, Zhang W, Hall J, Lareau C, Grupp SA, Fraietta JA, Sotillo E, Satpathy AT, Mackall CL, Weber EW. Doan A, et al. Among authors: grupp sa. Res Sq [Preprint]. 2023 Nov 7:rs.3.rs-2802998. doi: 10.21203/rs.3.rs-2802998/v1. Res Sq. 2023. PMID: 37986944 Free PMC article. Updated. Preprint.
FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, Lattin J, Markovska M, Mozarsky B, Arias-Umana J, Hapke R, Jung IY, Wang A, Xu P, Klysz D, Zuern G, Bashti M, Quinn PJ, Miao Z, Sandor K, Zhang W, Chen GM, Ryu F, Logun M, Hall J, Tan K, Grupp SA, McClory SE, Lareau CA, Fraietta JA, Sotillo E, Satpathy AT, Mackall CL, Weber EW. Doan AE, et al. Among authors: grupp sa. Nature. 2024 May;629(8010):211-218. doi: 10.1038/s41586-024-07300-8. Epub 2024 Apr 10. Nature. 2024. PMID: 38600391 Free PMC article.
Quality Improvement Initiative to Improve Time and Adherence to Revaccination after Hematopoietic Cell Transplantation: Implementation of a Revaccination Clinic within the Transplantation Program.
Elgarten C, Wohlschlaeger A, Levy E, Tadley K, Wang L, Atkinson M, Roberson H, Olson T, Bunin N, Heimall J, Fisher B, Grupp S, Freedman J. Elgarten C, et al. Transplant Cell Ther. 2023 Oct;29(10):635.e1-635.e8. doi: 10.1016/j.jtct.2023.07.020. Epub 2023 Jul 28. Transplant Cell Ther. 2023. PMID: 37517611
ACT To Sustain: Adoptive Cell Therapy To Sustain access to non-commercialized genetically modified cell therapies.
Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S, Oluwole OO, Rouce RH, Spiegel J, Shah NN, Sharma A, Komanduri K, Gill S. Gardner RA, et al. Among authors: grupp sa. Transplant Cell Ther. 2024 May 16:S2666-6367(24)00407-X. doi: 10.1016/j.jtct.2024.05.010. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38762057 Review.
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: grupp sa. Transplant Cell Ther. 2024 Apr;30(4):421-432. doi: 10.1016/j.jtct.2024.01.079. Epub 2024 Feb 4. Transplant Cell Ther. 2024. PMID: 38320730 Free article.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, Cavazzana M, Corbacioglu S, Rondelli D, Meisel R, Dedeken L, Lobitz S, de Montalembert M, Steinberg MH, Walters MC, Eckrich MJ, Imren S, Bower L, Simard C, Zhou W, Xuan F, Morrow PK, Hobbs WE, Grupp SA; CLIMB SCD-121 Study Group. Frangoul H, et al. Among authors: grupp sa. N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24. N Engl J Med. 2024. PMID: 38661449 Clinical Trial.
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng GW, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk FA, Choe HK, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E Prof Dr med, Ferrara JLM, Nakamura R, Levine JE, Chen YB. DeFilipp Z, et al. Among authors: grupp sa. Blood Adv. 2024 Apr 19:bloodadvances.2024012561. doi: 10.1182/bloodadvances.2024012561. Online ahead of print. Blood Adv. 2024. PMID: 38640197
250 results